716359-92-1Relevant academic research and scientific papers
Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist
He, Shuwen,Ye, Zhixiong,Dobbelaar, Peter H.,Sebhat, Iyassu K.,Guo, Liangqin,Liu, Jian,Jian, Tianying,Lai, Yingjie,Franklin, Christopher L.,Bakshi, Raman K.,Dellureficio, James P.,Hong, Qingmei,Tsou, Nancy N.,Ball, Richard G.,Cashen, Doreen E.,Martin, William J.,Weinberg, David H.,MacNeil, Tanya,Tang, Rui,Tamvakopoulos, Constantin,Peng, Qianping,Miller, Randy R.,Stearns, Ralph A.,Chen, Howard Y.,Chen, Airu S.,Strack, Alison M.,Fong, Tung M.,MacIntyre, D. Euan,Wyvratt Jr., Matthew J.,Nargund, Ravi P.
scheme or table, p. 2106 - 2110 (2010/08/19)
We report the design, synthesis and properties of spiroindane based compound 1, a potent, selective, orally bioavailable, non-peptide melanocortin subtype-4 receptor agonist. Compound 1 shows excellent erectogenic activity in the rodent models.
ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
-
Page/Page column 67-68, (2010/11/27)
Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
